Q1 FY27 results reported
As filed · Press Release
What happened
FactUnit: Sai Parenterals Limited. the Press Release on the Standalone & Consolidated Un-audited financial results for the quarter ended.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Margins
RevisedQ4FY26 revenue stood at X197.93 crores with growth of 166.65% on Q-o-Q basis; EBITDA stood at X28.97 crores with growth of 366.97% on Q-o-Q basis; PAT stood at X13.25 crores with growth of 736.04% on Q-o-Q basis;
FY26 revenue stood at X380.99 crores with growth of 140.37% on Y-o-Y basis; EBITDA stood at X47.21 crores with growth of 33.29% on Y-o-Y basis; and PAT stood at X14.37 crores with growth of 45.52% on Y-o-Y basis
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- With ongoing capex of ~%440 crores expected to be completed in FY27, we believe the company is well positioned (management committed by FY27)
- The Construction of Australia’s largest and most modern pharmaceutical plant built with Capex of AUD 53 millio (management committed by Q4FY27)
Evidence
- Sai Parenterals Limited has informed the Exchange regarding a press release dated August 11, 2026, titled "Investor Press Release for Quarter ender 30.06.2026".(opens the original filing in a new tab)
- Earlier statement · Q4 FY26
- Latest statement · Q4 FY26
- Earlier statement · Q4 FY26
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +2 corroborating keywords; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%